Stifel Nicolaus Cuts Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $1.00

Bolt Biotherapeutics (NASDAQ:BOLT) had its target price trimmed by Stifel Nicolaus from $1.25 to $1.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a hold rating on the stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a report on Tuesday, March 25th.

Bolt Biotherapeutics Stock Performance

Shares of BOLT opened at $0.32 on Tuesday. The company has a market capitalization of $12.15 million, a price-to-earnings ratio of -0.19 and a beta of 0.96. Bolt Biotherapeutics has a 52-week low of $0.30 and a 52-week high of $0.89. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The stock has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.48.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its earnings results on Monday, May 12th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.05. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The firm had revenue of $1.22 million for the quarter, compared to the consensus estimate of $0.77 million. Research analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Trading of Bolt Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Velan Capital Investment Management LP purchased a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at about $27,000. Squarepoint Ops LLC acquired a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $26,000. Millennium Management LLC acquired a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $25,000. Finally, Citadel Advisors LLC purchased a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at approximately $42,000. Hedge funds and other institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.